- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05820074
Investigating Neural Biomarkers for Gait in Parkinson's Patients
This observational study's main goal is to learn more about the neural mechanisms during movement in Parkinson's disease. Furthermore, it aims to inspire personalised treatment options.
Participants will undergo a protocol that involves walking and gait-related motor tasks, such as seated stepping. During the protocol, brain activity will be recorded.
Study Overview
Status
Conditions
Detailed Description
Parkinson's Disease (PD) is the second most common neurodegenerative disease accompanied by motor impairment [1]. Although symptomatic treatments like medication with Dopamine equivalents and deep brain stimulation (DBS) are available, the effects are very heterogeneous among patients and often cease over time.
This study aims to generate insights into the neural mechanisms of PD by determining neural biomarkers for gait. The insights of this study may further inspire personalised treatment approaches.
The primary objective is to identify neural biomarkers for gait. It is hypothesised that characteristic neural oscillations are underlying kinematic patterns in healthy participants and PD patients.
The secondary objective is to compare the neural activity during gait and a seated lower limb motor task between healthy participants and PD patients. To this end, the investigators hypothesise that neural correlates of gait and of a seated lower limb motor task differ between healthy participants and PD patients.
60 participants will be included, 30 healthy participants and 30 PD patients. All participants must be older than 18 years and give informed consent. Potential participants will be pre-screened and will be informed about the study via phone call/email. Before any study procedure, participants will give informed consent as documented by signature. Afterwards, inclusion/exclusion criteria, medical history and participant characteristics will be assessed. PD patients must be of postural instability and gait difficulty sub-type.
The study consists of one session of approximately 2.5 hours. During this session, electroencephalography (EEG) in healthy participants and EEG + local field potentials of the subthalamic nucleus from implanted DBS-electrodes in PD patients will be recorded during standardised gait sequences and a seated lower limb motor task. Furthermore, a short-term neuromodulation task will be investigated.
Gait-related parameters will be recorded using motion capture, surface electromyography (EMG) and accelerometers. Gait characteristics, including symmetry, coordination, variability, and resilience will be assessed. All recording devices are approved on the market. The protocol of the session slightly differs between healthy participants and PD patients since no DBS electrodes are implanted in healthy participants, but still allows for comparison between the groups.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Lena Salzmann, MSc
- Phone Number: +41788248679
- Email: lena.salzmann@hest.ethz.ch
Study Contact Backup
- Name: Olivier Lambercy, PhD
- Email: oliver.lambercy@hest.ethz.ch
Study Locations
-
-
Luzern
-
Vitznau, Luzern, Switzerland, 6354
- Recruiting
- Cereneo
-
Contact:
- Andreas Luft, Professor
- Phone Number: +41 44 255 55 11
- Email: andreas.luft@usz.ch
-
Contact:
- Lena Salzmann, PhD student
- Phone Number: +41 44 510 72 34
- Email: lena.salzmann@hest.ethz.ch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
All participants
- must have given informed consent as documented by signature
- agree to comply with the study procedures
Healthy control group
- no neurological, orthopedic, or rheumatologic disease history
- no identified sensory impairment.
- no epilepsy and self-diagnosed acute or chronic psychiatric disorders
Parkinson's Patients
- non-tremor dominant idiopathic PD patients
- presence of postural instability (UPDRS >1 for postural instability [17]), gait disturbance, and absence of other causes of reduced balance
- Implanted with Percept™ PC neurostimulator
- Able to be in the stimulation OFF
Exclusion Criteria:
- Relevant cognitive impairment, with a score on Montréal Cognitive Assessment (MoCA) < 20
- History of physical or neurological condition that interferes with study procedures
- Social and/or personal circumstances interfering with the ability to come to the session
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Young, healthy control
Young healthy participants below 45 years will take part in a gait protocol involving treadmill walking with pertubations and overground walking including obstacle stepping, figure-8-walk and timed-up-and-go test, as well as a seated-stepping section. During the protocol, neural activity is recorded using EEG. |
Neural Activity is measured using EEG in all groups.
Additionally, in Parkinson's patients, local-field-potentials from deep brain stimulation electrodes are recorded.
Other Names:
Gait-related movement parameters are non-invasively recorded using motion capture, accelerometers and electromyography.
Other Names:
|
Age-matched healthy control
Age-matched healthy participants above 45 years will take part in a gait protocol involving treadmill walking with pertubations and overground walking including obstacle stepping, figure-8-walk and timed-up-and-go test, as well as a seated-stepping section. During the protocol, neural activity is recorded using EEG. |
Neural Activity is measured using EEG in all groups.
Additionally, in Parkinson's patients, local-field-potentials from deep brain stimulation electrodes are recorded.
Other Names:
Gait-related movement parameters are non-invasively recorded using motion capture, accelerometers and electromyography.
Other Names:
|
Parkinson's patients
Parkinson's patients will take part in a gait protocol involving treadmill walking with pertubations and overground walking including obstacle stepping, figure-8-walk and timed-up-and-go test, as well as a seated-stepping section. Additionally, a neuromodulation set-up will be tested. During the protocol, neural activity is recorded using EEG and signals from the DBS-electrodes. |
Neural Activity is measured using EEG in all groups.
Additionally, in Parkinson's patients, local-field-potentials from deep brain stimulation electrodes are recorded.
Other Names:
Gait-related movement parameters are non-invasively recorded using motion capture, accelerometers and electromyography.
Other Names:
Neural signals are recorded with the electrodes of the deep brain stimulation device.
Parkinson's patients are asked to modulate their neural activity by observing the streamed neural activity and applying mental strategies.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cortical activity underlying kinematic gait patterns will be recorded by electroencephalograph of the healthy and Parkinson patients
Time Frame: 30 minutes
|
Using a mobile EEG system to measure neural activity during walking
|
30 minutes
|
Electromyography (Delsys®) of the healthy and Parkinson patients
Time Frame: 30 minutes
|
Electrodes will be attached to a representative lower limb muscle, such as the tibialis anterior.
|
30 minutes
|
Detect onset of task-related movements detected by an accelerometer that will be placed on the hand and foot of the healthy and the parkinson patients
Time Frame: 30 minutes
|
ZurichMOVE® detects onset of movements
|
30 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare cortical activity between healthy subjects and parkinson patients
Time Frame: 30 minutes
|
Neural activity between healthy controls and partient cohort will be compared.
|
30 minutes
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in movement frequency between healthy participants and PD patients
Time Frame: 15 minutes
|
Analysing the difference between healthy subjects and PD patients
|
15 minutes
|
Difference in the range of motion between healthy participants and PD patients
Time Frame: 15 minutes
|
Analysing the difference between healthy subjects and PD patients
|
15 minutes
|
Collaborators and Investigators
Investigators
- Principal Investigator: Olivier Lambercy, PhD, RELab, ETH Zürich
Publications and helpful links
General Publications
- Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE. Parkinson disease. Nat Rev Dis Primers. 2017 Mar 23;3:17013. doi: 10.1038/nrdp.2017.13.
- Ravi DK, Gwerder M, Konig Ignasiak N, Baumann CR, Uhl M, van Dieen JH, Taylor WR, Singh NB. Revealing the optimal thresholds for movement performance: A systematic review and meta-analysis to benchmark pathological walking behaviour. Neurosci Biobehav Rev. 2020 Jan;108:24-33. doi: 10.1016/j.neubiorev.2019.10.008. Epub 2019 Oct 19.
- Rodriguez-Oroz MC, Moro E, Krack P. Long-term outcomes of surgical therapies for Parkinson's disease. Mov Disord. 2012 Dec;27(14):1718-28. doi: 10.1002/mds.25214. Epub 2012 Dec 3.
- Bichsel O, Stieglitz LH, Oertel MF, Baumann CR, Gassert R, Imbach LL. Deep brain electrical neurofeedback allows Parkinson patients to control pathological oscillations and quicken movements. Sci Rep. 2021 Apr 12;11(1):7973. doi: 10.1038/s41598-021-87031-2.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-01382 NGB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Neural Activity Recording
-
University Hospital, MontpellierReims University Hospital; Institute for Neurosciences of Montpellier U1051Completed
-
Vanderbilt University Medical CenterEdwards LifesciencesCompletedAortic Valve StenosisUnited States
-
NYU Langone HealthCompletedFibromyalgiaUnited States
-
Northwestern UniversityRecruiting
-
Medical University of ViennaAustrian Science Fund (FWF)Active, not recruitingHeart Failure | Artificial Heart Device UserAustria
-
Johns Hopkins UniversityTerminatedInflammatory Bowel DiseasesUnited States
-
Centre Hospitalier Universitaire, AmiensUniversity Hospital, Strasbourg, France; University Hospital, Brest; University... and other collaboratorsRecruitingPreterm NewbornFrance
-
Josue Fernandez CarneroUniversidad Autonoma de MadridCompleted
-
Frank LobbezooCompletedSleep Bruxism | Dental Implant ComplicationsNetherlands
-
Centre Hospitalier Universitaire, AmiensCompleted